Deven C. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Deven C. Patel has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Douglas Z. Liou
Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA, USA
4 shared publications- Mark F. Berry
Department of Cardiothoracic Surgery, Stanford University, Stanford, CA
4 shared publications Chi-Fu Jeffrey Yang
Division of Thoracic Surgery, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, USA
2 shared publicationsHao He
Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA, USA
2 shared publicationsMark F. Berry
Department of Cardiothoracic Surgery, Division of Thoracic Surgery, Stanford University Medical Center, Stanford, California
2 shared publications- Natalie S. Lui
Department of Cardiothoracic Surgery, Stanford University, 300 Pasteur Dr Falk Cardiovascular Research Building, Stanford, CA 94305-5407, USA
2 shared publications
Latest Publications
- Open Access
- 2 August 2024
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 25 (4) , 141-148
Population-Based Analysis of Local Therapies for Large (>7 cm) Non-Small Cell Lung Cancer Tumors
Non-small cell lung cancer,large tumors,surgery,radiation therapy,survival,comparative effectiveness
- 2 August 2024
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 25 (4) , 141-148
Open AccessPopulation-Based Analysis of Local Therapies for Large (>7 cm) Non-Small Cell Lung Cancer Tumors
Non-small cell lung cancer,large tumors,surgery,radiation therapy,survival,comparative effectiveness
- Open Access
- 23 May 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (9) , 5931
ASO Visual Abstract: Treatment and Outcomes of Proximal Esophageal Squamous Cell Carcinoma
- 23 May 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (9) , 5931
Open AccessASO Visual Abstract: Treatment and Outcomes of Proximal Esophageal Squamous Cell Carcinoma
- 28 October 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (2) , 818-827
Treatment and Outcomes of Proximal Esophageal Squamous Cell Carcinoma
This study evaluated the treatment of proximal (cervical or upper thoracic) esophageal squamous cell carcinoma (SCC), for which chemoradiation is the recom
- 28 October 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (2) , 818-827
Treatment and Outcomes of Proximal Esophageal Squamous Cell Carcinoma
This study evaluated the treatment of proximal (cervical or upper thoracic) esophageal squamous cell carcinoma (SCC), for which chemoradiation is the recom
- 18 October 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (2) , 828-829
ASO Author Reflections: Optimizing Proximal Esophageal Squamous Cell Carcinoma Treatment
- 18 October 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (2) , 828-829
ASO Author Reflections: Optimizing Proximal Esophageal Squamous Cell Carcinoma Treatment
- 11 November 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 270, 413-420
Perioperative Outcomes After Combined Esophagectomy and Lung Resection
- 11 November 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 270, 413-420
Perioperative Outcomes After Combined Esophagectomy and Lung Resection
- 5 November 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 270, 405-412
Percutaneous Cholecystostomy Tube for Acute Cholecystitis: Quantifying Outcomes and Prognosis
- 5 November 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 270, 405-412
Percutaneous Cholecystostomy Tube for Acute Cholecystitis: Quantifying Outcomes and Prognosis
Cancer diagnoses and survival rise as 65‐year‐olds become Medicare‐eligible
Background: A Medicare effect has been described to account for increased health care utilization occurring at the age of 65 years. The existence of such an effect in cancer care, where it would be most likely to reduce mortality, has been unclear.Methods: Patients aged 61 to 69 years who were diagnosed with lung, breast, colon, or prostate cancer from 2004 to 2016 were identified with the Surveillance, Epidemiology, and End Results database and were dichotomized on the basis of eligibility for Medicare (61‐64 vs 65‐69 years). With age‐over‐age (AoA) percent change calculations, trends in cancer diagnoses and staging were characterized. After matching, uninsured patients who were 61 to 64 years old (pre‐Medicare group) were compared with insured patients who were 65 to 69 years old (post‐Medicare group) with respect to cancer‐specific mortality.Results: In all, 134,991 patients were identified with lung cancer, 175,558 were identified with breast cancer, 62,721 were identified with colon cancer, and 238,823 were identified with prostate cancer. The AoA growth in the number of cancer diagnoses was highest at the age of 65 years in comparison with all other ages within the decade for all 4 cancers (P < .01, P < .001, P < .01, and P < .001, respectively). In a comparison of diagnoses at the age of 65 years with those in the 61‐ to 64‐year‐old cohort, the greatest difference for all 4 cancers was seen in stage I. In matched analyses, the 5‐year cancer‐specific mortality was worse for lung (86.3% vs 78.5%; P < .001), breast (32.7% vs 11.0%; P < .001), colon (57.1% vs 35.6%; P < .001), and prostate cancer (16.9% vs 4.8%; P < .001) in the uninsured pre‐Medicare group than the insured post‐Medicare group.Conclusions: The age threshold of 65 years for Medicare eligibility is associated with more cancer diagnoses (particularly stage I), and this results in lower long‐term cancer‐specific mortality for all cancers studied.Lay Summary: Contributing to the current debate regarding Medicare for all, this study shows that the expansion of Medicare would improve cancer outcomes for the near elderly.
Cancer diagnoses and survival rise as 65‐year‐olds become Medicare‐eligible
Background: A Medicare effect has been described to account for increased health care utilization occurring at the age of 65 years. The existence of such an effect in cancer care, where it would be most likely to reduce mortality, has been unclear.Methods: Patients aged 61 to 69 years who were diagnosed with lung, breast, colon, or prostate cancer from 2004 to 2016 were identified with the Surveillance, Epidemiology, and End Results database and were dichotomized on the basis of eligibility for Medicare (61‐64 vs 65‐69 years). With age‐over‐age (AoA) percent change calculations, trends in cancer diagnoses and staging were characterized. After matching, uninsured patients who were 61 to 64 years old (pre‐Medicare group) were compared with insured patients who were 65 to 69 years old (post‐Medicare group) with respect to cancer‐specific mortality.Results: In all, 134,991 patients were identified with lung cancer, 175,558 were identified with breast cancer, 62,721 were identified with colon cancer, and 238,823 were identified with prostate cancer. The AoA growth in the number of cancer diagnoses was highest at the age of 65 years in comparison with all other ages within the decade for all 4 cancers (P < .01, P < .001, P < .01, and P < .001, respectively). In a comparison of diagnoses at the age of 65 years with those in the 61‐ to 64‐year‐old cohort, the greatest difference for all 4 cancers was seen in stage I. In matched analyses, the 5‐year cancer‐specific mortality was worse for lung (86.3% vs 78.5%; P < .001), breast (32.7% vs 11.0%; P < .001), colon (57.1% vs 35.6%; P < .001), and prostate cancer (16.9% vs 4.8%; P < .001) in the uninsured pre‐Medicare group than the insured post‐Medicare group.Conclusions: The age threshold of 65 years for Medicare eligibility is associated with more cancer diagnoses (particularly stage I), and this results in lower long‐term cancer‐specific mortality for all cancers studied.Lay Summary: Contributing to the current debate regarding Medicare for all, this study shows that the expansion of Medicare would improve cancer outcomes for the near elderly.
- Open Access
- 1 September 2020
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 155 (9) , 888-889
Patient Expectations After Collis Gastroplasty
When repairing large hiatal hernias (HH) and encountering a short esophagus (SE), surgeons are presented with the option of performing a higher mediastinal dissection or creating a Collis gastroplasty (CG). Collis gastroplasty is a procedure that creates a neoesophagus below the gastroesophageal junction by removing a portion of the gastric fundus. In addition to the technical challenge of creating a CG, surgeons have concerns about potential staple line leaks, as well as the long-term effects of an aperistaltic neoesophagus with acid-secreting gastric tissue above the fundoplication.1,2 This study was undertaken to review the short- and long-term outcomes in patients who have undergone a CG with fundoplication and HH repair.
- 1 September 2020
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 155 (9) , 888-889
Open AccessPatient Expectations After Collis Gastroplasty
When repairing large hiatal hernias (HH) and encountering a short esophagus (SE), surgeons are presented with the option of performing a higher mediastinal dissection or creating a Collis gastroplasty (CG). Collis gastroplasty is a procedure that creates a neoesophagus below the gastroesophageal junction by removing a portion of the gastric fundus. In addition to the technical challenge of creating a CG, surgeons have concerns about potential staple line leaks, as well as the long-term effects of an aperistaltic neoesophagus with acid-secreting gastric tissue above the fundoplication.1,2 This study was undertaken to review the short- and long-term outcomes in patients who have undergone a CG with fundoplication and HH repair.